Intellia Therapeutics Cash Flow Statement
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Intellia Therapeutics free cash flow
In fiscal 2025, Intellia Therapeutics generated -$394.7 million of operating cash flow and spent $1.1 million on capital expenditures. That left free cash flow of -$395.9 million, a free-cash-flow margin of -585.0% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Intellia Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M | -134.23M | -99.53M | -85.34M | -67.54M | -31.63M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 9.77M | 10.29M | 8.98M | 7.57M | 6.89M | 6.31M | 5.59M | 4.46M | 2.99M | 1.10M |
| Stock-Based Compensation | 80.22M | 154.27M | 134.05M | 91.40M | 47.01M | 19.90M | 15.09M | 17.05M | 15.32M | 6.71M |
| Change in Working Capital | -25.54M | 3.20M | -27.63M | -54.95M | -13.35M | 65.78M | -19.85M | 3.02M | -14.20M | 60.92M |
| Operating Cash Flow | -394.74M | -348.88M | -394.09M | -333.29M | -225.03M | -49.91M | -103.24M | -61.26M | -65.28M | 36.11M |
| Capital Expenditures | -1.13M | -5.78M | -13.98M | -13.56M | -12.76M | -3.58M | -6.79M | -6.36M | -10.09M | -6.17M |
| Investing Cash Flow | 228.03M | 125.57M | -31.35M | 160.31M | -550.78M | -214.49M | 25.18M | -260.78M | -10.09M | -6.17M |
| Financing Cash Flow | 131.49M | 185.75M | 130.32M | 582.96M | 736.69M | 371.78M | 76.43M | 40.22M | 142.98M | 167.30M |
| Net Change in Cash | -35.22M | -37.57M | -295.11M | 409.98M | -39.12M | 107.38M | -1.63M | -281.82M | 67.61M | 197.25M |
| Free Cash Flow | -395.87M | -354.66M | -408.07M | -346.85M | -237.79M | -53.50M | -110.03M | -67.61M | -75.37M | 29.94M |
This table shows 10 annual periods of Intellia Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NTLA's reporting calendar. What is a cash flow statement?